Drugs / LioCyx
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03634683 | Aug 2018 → Aug 2022 | hepatocellular carcinoma | Lion TCR Pte. Ltd. | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-09-23 | Lion TCR Pte. Ltd. | Regulatory Lion TCR Announces FDA Clearance of its IND Application for its Lead Investigational Product, LioCyx-M004, for Hepatocellular Carcinoma liontcr.com ↗
Lion TCR Pte Ltd, a clinical-stage biotech company specialized in T Cell Receptor (TCR) T cell therapy today announced that it has received clearance from U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) Application for LioCyx-M004, autologous T-cells transfected with mRNA encoding Hepatitis B surface antigen (HBsAg) specific TCR. |
| 2018-08-19 | Lion TCR Pte. Ltd. | Regulatory Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer liontcr.com ↗
Aug 19, 2018 – Lion TCR Pte. Ltd., a Singapore-based Biotech company receives approval from Health Sciences Authority (HSA), Singapore, for its Phase I/II multicentre clinical study of its product candidate (LioCyx™) for treatment of relapsed liver cancer post-liver transplantation. |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LioCyx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03634683 ↗ |
| Action | Deplete | “LioCyx is capable of lysing target liver cells expressing the HBV cognate antigens” NCT03634683 ↗ |
| Modality | Cell therapy | “Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR” NCT03634683 ↗ |